Government revises NLEM: cuts prices for 39 commonly used drugs

By revising the “National Essential Medicines List” (NLEM), the central government reduced the prices of 39 commonly used drugs.

Prices have been reduced for anti-cancer, anti-diabetic, anti-viral, anti-bacterial, anti-retroviral, anti-tuberculosis drugs, and also for some that are used in Covid treatment.

Experts working on the NLEM list have removed 16 strange drugs from the list.

The Indian Council of Medical Research (ICMR) has long worked to expand drug price controls.

Commonly used drugs, which have been cut below the price cap, include teneligliptin – an anti-diabetic drug, popular anti-tuberculosis drugs, ivermectin – used in the treatment of Covid, the rotavirus vaccine, among others.

The government had started an exercise to revise the NLEM, which was notified in 2015 and implemented in 2016.

This is a departure from the current practice, where all essential drugs are automatically subject to price controls.

The National Standing Medicines Committee has been tasked with preparing the list of medicines which should be available in sufficient numbers and in guaranteed quantities.

The committee headed by Balram Bhargava, secretary of the health research department and director general of ICMR, sends the list to a second committee made up of senior officials from NITI Aayog, secretary of health and secretary of the pharmaceuticals department, who decides which drugs to put under the price cap.

–IANS

apr / shs / ​​in

(Only the title and image of this report may have been reworked by Business Standard staff; the rest of the content is automatically generated from a syndicated feed.)

Dear reader,

Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting edge commentary on relevant current issues.
However, we have a demand.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital editor


Source link

Comments are closed.